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is	 to	 describe	 the	 obstetric	 and	maternal	 outcome	of	women	with	 gastric	 cancer	
during	pregnancy	and	review	the	literature	on	antenatal	chemotherapy	for	gastric	
cancer.
Material and methods: Treatment	 and	 outcome	 of	 patients	 registered	 in	 the	
International	 Network	 on	 Cancer,	 Infertility	 and	 Pregnancy	 database	with	 gastric	
cancer	diagnosed	during	pregnancy	were	analyzed.
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1  | INTRODUC TION
Gastric	cancer	is	one	of	the	most	common	cancers,	with	very	specific	
geographical,	 ethnic	 and	 socioeconomic	 differences	 in	 incidence.	





pressive	disease.	Exposure	 to	Helicobacter pylori	 plays	a	 role	 in	 the	







Gastric	 cancer	 is	 staged	 according	 to	 the	 American	 Joint	
Committee	on	Cancer/Union	for	International	Cancer	Control	TNM	
staging	system,	based	upon	tumor	size	(T),	lymph	node	invasion	(N),	
and	 metastatic	 disease	 (M).	 Early	 gastric	 cancer	 is	 limited	 to	 the	
mucosa	 or	 submucosa	 (T1),	 whereas	 the	 tumor	 is	 assumed	 to	 be	
clinically	 localized	once	 the	muscular	 layer	 (T2)	 is	 invaded.	Stage	 I	




lymph	 nodes	 affected	 or	 distant	 organs.	 The	 stage	 distribution	 in	
the	general	population	is	21.6%	for	stage	I,	22.3%	for	stage	II,	44.0%	
for	 stage	 III,	 and	12.1%	 for	 stage	 IV.4	Pregnant	women	are	at	 risk	
for	delayed	diagnosis	of	gastric	cancer	because	symptoms	may	be	
regarded	as	gestational	 features	and	because	of	 the	 reluctance	 to	
perform	invasive	diagnostic	procedures	such	as	gastroscopy.5	As	a	








pyrimidine‐based	 regimen,	 such	as	FOLFOX	 (5‐fluorouracil	 [5‐FU],	
leucovorin	and	oxaliplatin),	CAPOX	(capecitabine,	oxaliplatin),	ECF/
ECC	(epirubicin,	cisplatin,	5‐FU/capecitabine)	or	EOX	(epirubicin,	ox‐




Various	 chemotherapy	 regimens	 are	 feasible	during	pregnancy	
without	 an	 increased	 risk	 of	 congenital	 malformations	 if	 adminis‐
tered	after	the	first	trimester.7	More	pregnant	women	with	cancer	































pregnancy	might	 be	 considered	 if	 parents	 are	 counseled	
for	neonatal	risks.
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while	avoiding	preterm	birth	or	pregnancy	termination	as	much	as	
possible.7	 To	 date,	 the	 relative	 safety	 of	 antenatal	 chemotherapy	
is	mainly	demonstrated	 for	 treatments	used	 in	breast	and	cervical	











2  | MATERIAL AND METHODS
All	women	diagnosed	with	primary	or	recurrent	gastric	cancer	dur‐
ing	pregnancy	were	selected	from	the	database	of	the	International	
Cancer	 in	 Pregnancy	 registration	 study	 (Clinicaltrials.gov,	 number	
NTC00330447).	 The	 registry	 contains	 retrospectively,	 and	 since	




contains	 2059	women	with	 a	 cancer	 diagnosis	 during	 pregnancy,	
registered	by	European	 (Belgium	25%,	 the	Netherlands	21%,	 Italy	
13%,	 Czech	 Republic	 6%)	 and	 non‐European	 (Philadelphia,	 USA	
13%,	 Russia	 8%,	 Mexico	 6%)	 centers.	 For	 the	 present	 study,	 pa‐
tient	 data	on	 treatment	 and	obstetrical	 outcomes	were	 collected.	
Referring	 physicians	 were	 contacted	 to	 complete	 missing	 data.	
Small‐for‐gestational‐age	(SGA)	was	defined	as	a	birthweight	below	
the	 10th	 centile,	 and	 centiles	were	 corrected	 for	 gestational	 age,	
sex,	maternal	height,	maternal	weight,	ethnicity,	and	parity	accord‐
ing	to	the	calculator	from	the	Gestation	Network	(www.gesta	tion.
















3.1 | Patient and tumor characteristics
In	 total,	 13	 women	 diagnosed	 with	 primary	 or	 recurrent	 gastric	









in	 Table	 1.	Median	maternal	 age	 at	 diagnosis	was	32	 years	 (range	
26‐39	 years),	 median	 gestational	 age	 at	 diagnosis	 was	 21	 weeks	





can	 still	 be	 fertile	 despite	 amenorrhea	 secondary	 to	 cancer	 treat‐
ment.	 Most	 women	 (9/13,	 69%)	 presented	 with	 gastrointestinal	
symptoms	 (nausea	 and	 vomiting	 [5/13,	 39%],	 diarrhea	 [1/13,	 8%],	
distended	 abdomen	 [3/13,	 23%]).	 One	 woman	 presented	 with	 a	
palpable	 cervical	 adenopathy.	 Because	 the	 origin	 of	 the	 primary	
tumor	was	initially	uncertain,	she	was	initiated	with	carboplatin	and	
paclitaxel	 during	pregnancy	 and	 switched	postpartum	 to	 cisplatin,	
doxorubicin	 and	 trastuzumab	when	 a	 computed	 tomography	 scan	
revealed	a	gastric	tumor.	Another	woman	presented	with	vertebral	
pain	 caused	 by	 bone	metastasis.	 Two	 had	 ascites,	 in	 combination	
with	liver	metastasis	or	peritoneal	metastasis.	Five	women	were	di‐
agnosed	with	ovarian	Krukenberg	tumors.
3.2 | Surgical and chemotherapeutic management 
during pregnancy
One	 woman	 with	 stage	 II	 cancer	 started	 with	 chemotherapy	 at	
23	weeks	of	gestation	 followed	by	curative	gastrectomy	after	de‐
livery.	In	total,	10	women	had	ongoing	pregnancies	with	inoperable	
gastric	 cancer	 and	 in	5	women	chemotherapy	was	 initiated	 in	 the	
second	 trimester	 of	 pregnancy.	 The	 chemotherapeutic	 regimens	
used	during	pregnancy	were:	5‐FU,	FOLFOX	and	carboplatin/pacli‐
taxel.	One	woman	underwent	surgery	with	a	curative	intent	but	was	





As	 described	 in	 Table	 1,	 there	was	 1	 termination	 of	 pregnancy,	 2	
pregnancy	 losses	 and	 10	 live	 births.	 One	 woman	 pregnant	 with	













All	 mothers	 with	 stage	 IV	 gastric	 cancer	 were	 deceased	 within	
24	months	after	pregnancy,	 the	majority	within	6	months.	Overall	 
1‐year	survival	was	31%.	The	only	woman	 in	remission	12	months	
after	 diagnosis	 had	 stage	 II	 gastric	 cancer	 and	 was	 treated	 with	
chemotherapy	during	pregnancy	followed	by	gastrectomy.
3.5 | Outcome of the children
In	total	10	pregnancies	ended	 in	a	 live	birth.	All	6	neonates	pre‐





of	methadone.	 Two	 neonates	 prenatally	 exposed	 to	 chemother‐
apy,	 to	6	cycles	FOLFOX	and	3	cycles	carboplatin/paclitaxel,	 re‐
spectively,	 (2/6	 or	 33%)	were	 SGA	 at	 birth.	 The	 4	 non‐exposed	
neonates	 were	 admitted	 to	 the	 neonatal	 intensive	 care	 unit	 for	
prematurity	and	2	of	them	where	SGA	(2/4	or	50%).	The	neonatal	
period	of	1	child	born	at	32	weeks	of	gestation,	2	weeks	after	the	
last	 administration	 of	 carboplatin,	was	 complicated	 by	 a	Bacillus 
cereus	 infection	 with	 a	 cerebral	 abscess.	 This	 was	 treated	 with	
antibiotics,	but	 the	neonate	had	residual	cerebral	palsy,	epilepsy	
and	 hemianopia.	 Despite	 these	 symptoms	 requiring	 intensive	
physiotherapy,	 the	 child	 was	 doing	 well	 in	 cognitive	 develop‐





long‐term	 follow	up	of	4	children	 that	 are	 included	 in	 the	 INCIP	
study	is	shown	in	Table	2.
3.6 | Results of narrative literature review
The	largest	review	to	date	of	137	Japanese	women	with	pregnancy‐
associated	 gastric	 cancer	was	 published	 in	 2009;	 one‐third	 of	 the	
women	with	reported	timing	of	delivery	were	diagnosed	with	gastric	
cancer	 postnatally.3	 The	 authors	 identified	 that	 92.5%	 of	 the	 pa‐
tients	had	advanced	stage	gastric	cancer	and	the	diffuse	type	was	
the	 most	 common	 histological	 diagnosis.	 Maternal	 outcome	 was	
poor	with	1‐	and	2‐year	survival	rate	of	18.3%	and	15.1%.	A	review	




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In	 this	 case	 series	 the	 obstetrical	 and	maternal	 outcomes	 of	 13	
women	 with	 a	 diagnosis	 of	 primary	 or	 recurrent	 gastric	 cancer	
during	pregnancy	are	 reported.	Most	women	were	diagnosed	at	
an	 advanced	 stage	with	 a	 diffuse	 type	 adenocarcinoma,	 includ‐
ing	 8	women	with	 signet	 ring	 cell	 carcinoma.	 Larger	 case	 series	
had	 similar	 findings,	 but	 none	 of	 these	 studies	 reported	 on	 the	
use	 of	 chemotherapy	 during	 pregnancy	 or	 neonatal	 outcome	 in	
detail	and	most	included	a	large	percentage	of	women	diagnosed	
postnatally.3,8,9




of	 age	 if	 curative	 resection	 is	not	 achieved.15	Furthermore,	 in	 a	
retrospective	 analysis	 of	 clinical‐pathological	 features	 and	 out‐
come	of	4722	non‐pregnant	patients,	female	sex	was	significantly	
associated	with	a	younger	age	at	diagnosis,	poorly	differentiated	
adenocarcinoma	 and	 signet	 ring	 cell	 carcinoma.16	 Due	 to	 these	
features,	overall	survival	was	poorer	for	female	than	for	male	pa‐
tients,	 especially	 among	 patients	 younger	 than	 45	 years	 of	 age	
with	 advanced	 disease.	 The	 histological	 features	 of	 the	 gastric	
cancer	in	pregnant	patients	are	similar	to	those	reported	in	non‐
pregnant	 female	 patients.	 Nevertheless,	 gastric	 cancer	 during	
pregnancy	 has	 a	 poor	 prognosis	 with	 reported	 median	 overall	
survival	of	7	months	and	3‐year	overall	survival	of	23.3%.	One‐
year	overall	survival	in	this	series	was	31%	(4/13	alive	12	months	
after	 diagnosis).To	 evaluate	 the	 effect	 of	 pregnancy	 on	 gastric	
cancer,	 Lee	 et	 al	 compared	 15	 pregnant	 patients	 with	 53	 age‐















indicate	 poor	 survival	 and	 the	 absence	 of	 ERβ	 is	 associated	 with	
lymph	 node	metastasis.18	 However,	 the	 clinical	 significance	 of	 ER	
and	(if	there	is)	estrogen‐dependent	tumor	growth	in	gastric	cancer	
is	still	unclear.
There	 is	 no	 evidence	 of	 severe	 adverse	 neonatal	 outcome	 or	
increased	 risk	 of	 congenital	malformations	 if	 regimens	 are	 admin‐
istered	 after	 fetal	 organogenesis	 (occurring	 2‐8	 weeks	 after	 con‐
ception)	while	avoiding	preterm	delivery.7,19	The	degree	of	placental	
transfer	of	drugs	depends	on	molecular	weight,	lipophilicity,	ioniza‐
tion	 at	 physiological	 pH	 and	 plasma	 protein	 binding,	 besides	 drug	
dose	and	gestational	age	at	exposure.	Also,	 interaction	with	active	
drug	 transporters,	 like	 p‐glycoprotein	 and	 BCRP	 (Breast	 Cancer	








contractions.	 Interestingly	 all	 preterm	deliveries,	 except	 1,	were	
iatrogenic	 for	 oncological	 or	 obstetrical	 reasons.	 Four	 out	 of	 10	
infants	were	SGA	and	this	is	of	special	interest	because	perinatal	










Current	 recommendations	 for	 the	 management	 of	 pregnant	
women	 with	 a	 diagnosis	 of	 gastric	 cancer	 is	 based	 on	 available	
case series.3,5,8	Treatment	options	depend	on	gestational	age	and	









outcome,	 term	 delivery	 should	 always	 be	 aimed	 for	 if	 possible.	
When	perioperative	chemotherapy	 is	 indicated,	 cytotoxic	agents	












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































maturity	 if	 there	 is	 a	wish	 to	 continue	 pregnancy.	 In	 early	 preg‐
nancy,	and	especially	in	advanced	cases,	termination	of	pregnancy	
can	also	be	 considered.	Available	 case	 reports	on	 chemotherapy	
during	 pregnancy	 for	 gastric	 and	 colorectal	 cancer	 suggest	 that	
5‐FU‐based	 regimens	 (i.e.	 FOLFOX)	 are	 feasible.11‐14,26 In gen‐





cer	 treatment	 is	 responsible	 for	 impaired	 cognitive	 outcome.19 





the	 neonatal	 outcome	 in	 detail	 including	 follow	 up.	 Continuous	
prospective	registration	of	cases	will	facilitate	future	patient	coun‐
seling.	 International	collaboration	 is	welcomed	 in	order	 to	collect	
data	 in	 larger	 numbers	 to	 improve	 treatment	 approach	 during	
pregnancy.
5  | CONCLUSION
In	 summary,	 gastric	 cancer	 during	 pregnancy	 is	 a	 rare	 diagnosis.	





balancing	maternal	 and	 fetal	 risks,	 the	 initiation	 of	 chemotherapy	
during	pregnancy	may	be	considered	in	order	to	reach	fetal	maturity.
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